Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune Responses 6 Months After mRNA-1273 COVID-19 Vaccination and the Effect of a Third Vaccination in Patients with Inborn Errors of Immunity.
van Leeuwen LPM, Grobben M, GeurtsvanKessel CH, Ellerbroek PM, de Bree GJ, Potjewijd J, Rutgers A, Jolink H, van de Veerdonk FL, van Gils MJ, de Vries RD, Dalm VASH; VACOPID Research Group. van Leeuwen LPM, et al. J Clin Immunol. 2023 Aug;43(6):1104-1117. doi: 10.1007/s10875-023-01514-7. Epub 2023 May 26. J Clin Immunol. 2023. PMID: 37231290 Free PMC article.
A beacon in the dark: COVID-19 course in CVID patients from two European countries: Different approaches, similar outcomes.
Milito C, Firinu D, Bez P, Villa A, Punziano A, Lagnese G, Costanzo G, van Leeuwen LPM, Piazza B, Deiana CM, d'Ippolito G, Del Giacco SR, Rattazzi M, Spadaro G, Quinti I, Scarpa R, Dalm VASH, Cinetto F. Milito C, et al. Among authors: van leeuwen lpm. Front Immunol. 2023 Feb 8;14:1093385. doi: 10.3389/fimmu.2023.1093385. eCollection 2023. Front Immunol. 2023. PMID: 36845159 Free PMC article.
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
Tan NH, Geers D, Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Bogers S, van Dijk LLA, Gommers L, van Leeuwen LPM, Boerma A, Nijhof SH, van Dort KA, Koopmans MPG, Dalm VASH, Lafeber M, Kootstra NA, Huckriede ALW, van Baarle D, Zaeck LM, GeurtsvanKessel CH, de Vries RD, van der Kuy PHM; SWITCH ON Research Group. Tan NH, et al. Among authors: van leeuwen lpm. Lancet Infect Dis. 2023 Aug;23(8):901-913. doi: 10.1016/S1473-3099(23)00140-8. Epub 2023 Apr 21. Lancet Infect Dis. 2023. PMID: 37088096 Free PMC article. Clinical Trial.
Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program.
van Leeuwen LPM, Grobben M, GeurtsvanKessel CH, Ellerbroek PM, de Bree GJ, Potjewijd J, Rutgers A, Jolink H, van de Veerdonk FL, van Gils MJ, de Vries RD, Dalm VASH; VACOPID Research Group. van Leeuwen LPM, et al. Front Immunol. 2024 Apr 18;15:1390022. doi: 10.3389/fimmu.2024.1390022. eCollection 2024. Front Immunol. 2024. PMID: 38698851 Free PMC article.
Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters.
Zaeck LM, Tan NH, Rietdijk WJR, Geers D, Sablerolles RSG, Bogers S, van Dijk LLA, Gommers L, van Leeuwen LPM, Rugebregt S, Goorhuis A, Postma DF, Visser LG, Dalm VASH, Lafeber M, Kootstra NA, Huckriede ALW, Haagmans BL, van Baarle D, Koopmans MPG; SWITCH-ON Research Group; van der Kuy PHM, GeurtsvanKessel CH, de Vries RD. Zaeck LM, et al. Among authors: van leeuwen lpm. Nat Commun. 2024 May 18;15(1):4224. doi: 10.1038/s41467-024-48414-x. Nat Commun. 2024. PMID: 38762522 Free PMC article. Clinical Trial.
Orthopoxvirus-specific antibodies wane to undetectable levels 1 year after MVA-BN vaccination of at-risk individuals, the Netherlands, 2022 to 2023.
van Leeuwen LP, Shamier MC, Verstrepen BE, Götz HM, Schmitz KS, Akhiyate N, Wijnans K, Bogers S, van Royen ME, van Gorp EC, Koopmans MP, de Vries RD, GeurtsvanKessel CH, Zaeck LM. van Leeuwen LP, et al. Euro Surveill. 2024 Sep;29(38):2400575. doi: 10.2807/1560-7917.ES.2024.29.38.2400575. Euro Surveill. 2024. PMID: 39301741 Free PMC article.
The role of antibody-dependent enhancement in dengue vaccination.
Aynekulu Mersha DG, van der Sterren I, van Leeuwen LPM, Langerak T, Hakim MS, Martina B, van Lelyveld SFL, van Gorp ECM. Aynekulu Mersha DG, et al. Among authors: van leeuwen lpm. Trop Dis Travel Med Vaccines. 2024 Nov 1;10(1):22. doi: 10.1186/s40794-024-00231-2. Trop Dis Travel Med Vaccines. 2024. PMID: 39482727 Free PMC article.
A 29-mRNA host response test to identify bacterial and viral infections and to predict 30-day mortality in emergency department patients with suspected infections: A prospective observational cohort study.
Tong-Minh K, van Leeuwen L, Ramakers C, Chen UI, Liesenfeld O, Gommers D, van Gorp E, Endeman H, van der Does Y. Tong-Minh K, et al. Diagn Microbiol Infect Dis. 2024 Nov 26;111(3):116599. doi: 10.1016/j.diagmicrobio.2024.116599. Online ahead of print. Diagn Microbiol Infect Dis. 2024. PMID: 39657556 Free article.
Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals.
Zaeck LM, Lamers MM, Verstrepen BE, Bestebroer TM, van Royen ME, Götz H, Shamier MC, van Leeuwen LPM, Schmitz KS, Alblas K, van Efferen S, Bogers S, Scherbeijn S, Rimmelzwaan GF, van Gorp ECM, Koopmans MPG, Haagmans BL, GeurtsvanKessel CH, de Vries RD. Zaeck LM, et al. Among authors: van leeuwen lpm. Nat Med. 2023 Jan;29(1):270-278. doi: 10.1038/s41591-022-02090-w. Epub 2022 Oct 18. Nat Med. 2023. PMID: 36257333 Free PMC article.
15 results